Nuclear factor-κB (NF-κB) transcription factors play a key role in the pathogenesis of multiple
myeloma (MM). The survival, proliferation and chemoresistance of malignant plasma cells …

Multiple myeloma (MM) shows constitutive activation of canonical and noncanonical nuclear
factor κB (NF-κB) signaling via genetic mutations or tumor microenvironment (TME) …

Despite remarkable advancements in the treatment of multiple myeloma (MM), relapse
remains a challenge. However, the mechanisms underlying this disease remain unclear …

Multiple myeloma (MM) is the second most common hematologic malignancy. Bortezomib
(BOR), a first-generation proteasome inhibitor, is the basic agent for the treatment of MM and …

Reduced responsiveness of precursor B-acute lymphoblastic leukemia (BCP-ALL) to
chemotherapy can be inferred when leukemia cells persist after 28 days of initial treatment …

Summary Purpose Multiple Myeloma (MM) is considered an incurable, biologically
heterogeneous disease of the plasma cells. The clinical data on the association between …

Multiple myeloma (MM) is an incurable malignancy of germinal center-derived long-lived
plasma cells (PCs) that undergo clonal growth at multiple sites throughout the bone marrow …

Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis, originate from pluripotent hematopoietic …

Multiple myeloma (MM) is a haematological malignancy characterised by the proliferation of
clonal plasma cells in the bone marrow, usually leading to the secretion of a monoclonal …